A Phase II Randomized Trial of Prophylactic Gabapentin Plus Best Supportive Care Versus Best Supportive Care Alone for Patients Receiving Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Locoregionally-Advanced, HPV-Related Oropharyngeal Cancer: An Optima II Secondary Study
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Gabapentin (Primary)
- Indications Chemotherapy-induced damage; Radiation injuries
- Focus Therapeutic Use
- Acronyms PROGRESS Trial
- 29 Jul 2024 According to ClinicalTrials.gov, the trial was withdrawn as they were unable to accrue
- 29 Jul 2024 Status changed from recruiting to discontinued.
- 25 Jan 2024 Planned End Date changed from 1 Sep 2023 to 1 Sep 2025.